Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective

Citation:
Sonousi, A., H. A. Mahran, I. M. Ibrahim, M. N. Ibrahim, A. A. Elfiky, and W. M. Elshemey, "Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective", Pharmacological Reports, vol. 73, issue 6, pp. 1754 - 1764, 2021.

Abstract:

SARS-CoV-2 is a newly emerged human coronavirus that severely affected human health and the economy. The viral RNA-dependent RNA polymerase (RdRp) is a crucial protein target to stop virus replication. The adenosine derivative, remdesivir, was authorized for emergency use 10 months ago by the United States FDA against COVID-19 despite its doubtful efficacy against SARS-CoV-2.

Notes:

n/a

Related External Link